- The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients with Familial Chylomicronaemia Syndrome (FCS) diagnosed via genetic testing or clinical criteria1
- The UK National Institute for Health and Care Excellence (NICE) has also issued guidance recommending funding for NHS in England and Wales to use it as an option to treat genetically confirmed FCS in adults, in accordance with a commercial arrangement2
- People living with the rare disease FCS have a substantially higher risk of acute pancreatitis and related long-term complications due to extremely high triglyceride levels, often resulting in a reduced quality of life3
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) will have access to a newly licensed new treatment option available on the NHS to reduce extremely high levels of triglycerides (a type of fat) in their bloodstreams, if the response to diet and conventional triglyceride lowering therapies has been inadequate. REDEMPLO® (plozasiran) has received Marketing Authorisation as an adjunct to diet to reduce triglyceride levels in adult patients with FCS, diagnosed via genetic testing or clinical criteria.1 Following this marketing authorisation, NICE has issued Technology Appraisal guidance recommending funding for the NHS in England and Wales to use it as a treatment option to treat genetically confirmed FCS in adults if the response to diet and conventional triglyceride lowering therapies has been inadequate, in accordance with a commercial arrangement.2